12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Qsymia regulatory update

Vivus said it expects EMA's CHMP to issue a negative opinion next month for an MAA for obesity drug Qsiva phentermine/topiramate. Vivus President Peter Tam told BioCentury that the committee had no product-specific issues with Qsiva. He said preliminary feedback indicated that the committee...

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >